Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Valued at $2.47 Billion by 2029 With CAGR of 7.9% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market from 2024 to 2025?
Recently, the alpha-1 antitrypsin deficiency augmentation therapy market has experienced robust growth. The market size is projected to increase from $1.69 billion in 2024 to $1.82 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Factors such as better diagnostic procedures, awareness programs, clinical studies, and an aging population have fueled this growth in the historical period.
What Is the Projected Market Size of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
The market for alpha-1 antitrypsin deficiency augmentation therapy is projected to experience noteworthy expansion in the upcoming years, reaching a value of $2.47 billion in 2029 with an annual growth rate of 7.9%. This growth over the forecast period is mainly due to advances in telehealth and remote monitoring, precision medicine, and gene therapy. Expected trends to shape this duration include the constant data on security and effectiveness, focus on patient-oriented care models, tele-rehabilitation programs, and individualized dosage plans.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp
Who are the Major Competitors in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Outlook?
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.
What Is Fueling Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
The surge in respiratory ailments fosters the escalation of the alpha-1 antitrypsin deficiency augmentation therapy market. Afflictions impeding lung and respiratory system functions lead to breathing complications and lung function impairment. The therapy designed to alleviate respiratory diseases in patients suffering from alpha-1 antitrypsin deficiency replenishes the deficient protein. Its mechanism involves re-establishing the protease-antiprotease activity balance within the lungs, shielding the lung tissue against injury resulting from excessive neutrophil elastase activity, thereby curtailing inflammation. For example, the Centers for Disease Control and Prevention, a US national public health establishment, reported that the US recorded 8,300 cases of tuberculosis (TB) in March 2023, rising from 7,874 instances in 2021. Therefore, the escalating number of respiratory ailments fuels the alpha-1 antitrypsin deficiency augmentation therapy market expansion. The anticipated boost of the alpha-1 antitrypsin deficiency augmentation therapy market is due to an upsurge in clinical trials. Clinical trials involve biomedical or behavioural research studies carried out on humans to provide answers to specific queries about biomedical or behavioural interventions, which encompasses new treatments and previously known interventions that merit further study and comparison. Such trials play a critical role in formulating and authorising new AATD therapies and drugs. The rise in clinical trial numbers indicates growing enthusiasm towards developing novel AATD therapies, which could lead to the launch of new and more efficient treatments in the market. For instance, as per a report released by Xtalks, a Canada-based web news and information network in May 2023, the number of clinical studies registered on ClinicalTrials.gov stood at 452,604, a considerable increase from over 365,000 trials recorded in early 2021. As a result, the alpha-1 antitrypsin deficiency augmentation therapy market is stimulated by the increase in clinical trials.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp
Which Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segments Are Growing the Fastest?
The alpha-1 antitrypsin deficiency augmentation therapy market covered in this report is segmented –
1) By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira And Respreeza
2) By Route Of Administration: Oral, Injection, Inhalation
3) By End User: Hospitals, Specialty Clinics, Other End Users
Which Industry Trends Are Shaping the Future of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
Major firms in the acute respiratory distress syndrome (ARDS) market are concentrating on creating innovative treatments, such as recombinant technology-based drug development, in order to maintain their standing in the market. The process of manufacturing recombinant technology-based therapeutics involves the modification of a live organism’s DNA to produce specific proteins. For example, Inhibrx Inc., a biotechnology company from the US, announced in March 2022 that its INBRX-101 has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for alpha-1 antitrypsin deficiency (AATD) treatment. INBRX-101, which is a recombinant human AAT-Fc fusion protein, potentially needs to be administered only once a month. It aims to safely achieve and maintain the levels of AAT found in healthy individuals.
Access The Full Report Here:
Which Countries Are Leading the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006
This Report Delivers Insight On:
1. How big is the alpha-1 antitrypsin deficiency augmentation therapy market, and how is it changing globally?
2. Who are the major companies in the alpha-1 antitrypsin deficiency augmentation therapy market, and how are they performing?
3. What are the key opportunities and risks in the alpha-1 antitrypsin deficiency augmentation therapy market right now?
4. Which products or customer segments are growing the most in the alpha-1 antitrypsin deficiency augmentation therapy market?
5. What factors are helping or slowing down the growth of the alpha-1 antitrypsin deficiency augmentation therapy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
